A5081670036- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Metal complexes synthesis and properties
- Crystal structures of chemical compounds
- Crystallography and molecular interactions
- Ferrocene Chemistry and Applications
- Synthesis and biological activity
- Synthesis and Biological Evaluation
- Magnetism in coordination complexes
- Bioactive Compounds and Antitumor Agents
- Synthesis and Characterization of Heterocyclic Compounds
- Click Chemistry and Applications
- Synthesis and Reactivity of Sulfur-Containing Compounds
- Cancer therapeutics and mechanisms
- DNA and Nucleic Acid Chemistry
- Molecular Sensors and Ion Detection
- Metal-Organic Frameworks: Synthesis and Applications
- Synthesis of Organic Compounds
- Organometallic Compounds Synthesis and Characterization
- Nonlinear Optical Materials Research
- Natural Compound Pharmacology Studies
- Hemoglobinopathies and Related Disorders
- Inorganic and Organometallic Chemistry
- Phenothiazines and Benzothiazines Synthesis and Activities
- Lanthanide and Transition Metal Complexes
Universidade Federal de Ouro Preto
2016-2025
Tecnológico de Monterrey
2024
University College London
2023
Sabin Medicina Diagnostica (Brazil)
2023
Division of Chemistry
2020
Universidade Cruzeiro do Sul
2020
Universidade Federal de São Carlos
2009-2018
Center for Effective Philanthropy
2015
Universidade Federal de Alfenas
2006-2013
Universidade de São Paulo
2008-2012
A series of copper(I)–phosphine polypyridyl complexes have been investigated as potential antitumor agents. The [Cu(PPh3)2dpq]NO3 (2), [Cu(PPh3)2dppz]NO3 (3), [Cu(PPh3)2dppa]NO3 (4), and [Cu(PPh3)2dppme]NO3 (5) were synthesized by the reaction [Cu(PPh3)2NO3] with respective planar ligand under mild conditions. These copper fully characterized elemental analysis, molar conductivity, FAB-MS, NMR, UV–vis, IR spectroscopies. Interactions between these DNA using various spectroscopic techniques...
Triple-negative breast cancer (TNBC) is a highly aggressive subtype. The high rate of metastasis associated to the fact that these cells frequently display multidrug resistance, make treatment metastatic disease difficult. Development antitumor metal-based drugs was started with discovery cisplatin, however, severe side effects represent limitation for its clinical use. Ruthenium (Ru) complexes different ligands have been successfully studied as prospective drugs. In this work, we...
Combination of multifunctionalities into one compound is a rational strategy in medicinal chemical design, and have often been used with metallodrug-based compounds. In the present study, we synthesized novel ruthenium-based 5-fluorouracil complex [Ru(5-FU)(PPh3)2(bipy)]PF6 (PPh3 = triphenylphosphine; bipy 2,2'-bipyridine) enhanced cytotoxicity different cancer cells, assessed its apoptosis induction action human colon carcinoma HCT116 cells. The was characterized by infrared, cyclic...
Ru(<sc>ii</sc>)/lapachol complex shows significant selectivity for triple negative breast cancer (TNBC) compared to the non-tumor human epithelial cell line.
A new family of compounds is presented as potential carbon monoxide releasing molecules (CORMs). These compounds, based on tetrachlorocarbonyliridate(III) derivatives, were synthesized and fully characterized by X-ray diffraction, electrospray mass spectrometry, IR, NMR, density functional theory calculations. The rate CO release was studied via the myoglobin assay. results showed that depends nature sixth ligand, trans to CO, a significant modulation can be produced changing ligand....
The well-known anti-inflammatory drug diclofenac can form new ruthenium compounds with promising anti-tumor properties.
We have synthesized and characterized three new ruthenium(II) diphosphine complexes containing an acylthiourea ligand, with the general formula [Ru(DPEPhos)(O,S)(bipy)]PF6, where DPEPhos = bis(2-(diphenylphosphino)phenyl)ether, bipy 2,2'-bipyridine, O,S N,N-dimethyl-N'-(benzoyl)thiourea (1), N,N-dimethyl-N'-(furoyl)thiourea (2), N,N-dimethyl-N'-(thiophenyl)thiourea (3), by several physicochemical techniques. evaluated ruthenium for their cytotoxicity against two human cancer cell lines, A549...
New cytotoxic ruthenium(<sc>ii</sc>) compounds with mercaptopyridine derivatives inhibit human DNA topoisomerase IB and interact moderately BSA macromolecules.
Melanoma is the most aggressive and lethal skin cancer that affects thousands of people worldwide. Ruthenium complexes have shown promising results as chemotherapeutics, offering several advantages over platinum drugs, such potent efficacy, low toxicity, less drug resistance. Additionally, anthraquinone derivatives broad therapeutic applications, including melanoma. Thus, two new ruthenium with 1-hydroxy-9,10-anthraquinone were obtained: trans-[Ru(HQ)(PPh3)2(bipy)]PF6 (1)...
Cancer resistance to chemotherapeutic agents such as cisplatin presents a significant challenge, leading treatment failure and poor outcomes. Novel metal-based compounds offer promising strategy overcome drug enhance efficacy. Four Ru(II) complexes with fenamic acid derivatives were synthesized characterized: [Ru(L)(bipy)(dppp)]PF6, where L represents (HFen, complex 1), mefenamic (HMFen, 2), tolfenamic (HTFen, 3), flufenamic (HFFen, 4). Their composition was supported by molar conductivity,...
Abstract Acute myeloid leukemia (AML) is a deadly blood cancer caused by blasts that fail to develop properly. AML has significant relapse rate, which attributed subset of cells known as stem (LSCs). Herein, we evaluated the ability Ru(II)-thymine complex (RTC) with formula [Ru(PPh3)2(Thy)(bipy)]PF6 (where PPh3 = triphenylphosphine, Thy thymine, and bipy 2, 2'-bipyridine) suppress LSCs. RTC exhibited strong cytotoxicity against solid hematologic malignancies inhibited primary LSCs, evidenced...